FDA signs collaborative agreement with Dana Solutions to apply deep-learning algorithms for drug toxicity testing
Research Collaboration Agreement between Dana Solutions and FDA to advance the drug development process using Artificial Intelligence
(PRWEB) Palo Alto, CA, February 25, 2019: Dana Solutions LLC announced today that it has entered into a Research Collaboration Agreement with the US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research.
FDA and Dana Solutions will collaborate to leverage state-of-the-art Artificial Intelligence (AI) techniques to advance the drug development process. The research will apply Dana Solutions' deep learning platform to predict clinical toxic side effects of drugs applied to human cell culture models, including iPSC-derived cardiomyocytes and hepatocytes. The research will focus on in vitro structural toxicity, with a goal of demonstrating improved sensitivity over existing functional assays and improved prediction of in vivo toxicity.
Managing Member of Dana Solutions, Dr. Mahnaz Maddah said: "Through this collaborative agreement, we will work with FDA to establish how AI can improve the drug development process, with a focus on drug safety testing. The combination of human iPSC-derived cell models with our deep learning platform represents an emerging technology with potential to shift the paradigms on drug safety assessment."
This collaboration fits within the FDA’s Strategic Plan for Regulatory Science and priority areas of evaluating innovative new technologies and improving health outcomes.
About Dana Solutions LLC:
Dana Solutions develops Artificial Intelligence solutions for the life sciences industry. We partner with companies in medical devices and biotechnology, as well as academia and government institutions, to develop breakthrough products and enable new scientific discoveries.